Evidence map›Paper›PMID 41372338›Full record

ArticleScientific reports2025

ParkMAE: a cross-linguistic masked autoencoder framework for robust Parkinson's disease detection from speech.

Angelika Ando, Adrien Lesage, Marc De Gennes, Rachid Riad

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Angelika Ando *Callyope, Paris, France.
Adrien Lesage *Callyope, Paris, France.
Marc De Gennes *Callyope, Paris, France.
Rachid RiadCallyope, Paris, France. rachid@callyope.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We introduce ParkMAE, a robust multilingual speech foundation model and comprehensive benchmarking system for Parkinson's disease assessment. We curated multiple large-scale speech datasets comprising approximately 750 h of pretraining data and 100 h of evaluation data across four languages and diverse clinical populations. Our self-supervised masked autoencoder approach, pretrained on this multilingual corpus, demonstrates superior performance achieving 39% F1 score for cross-linguistic diagnosis, outperforming existing acoustic markers (eGeMAPS) by a significant margin and maintaining comparable performance to generic speech models (Whisper), while using 89% fewer parameters. Besides, ParkMAE shows exceptional generalizability to unseen languages without language-specific finetuning. Beyond diagnosis, we systematically evaluate medication state monitoring and disease staging tasks, revealing that despite promising literature reports, current publicly available datasets and speech-based approaches fail to reliably capture these clinical dimensions. For cognitive assessment (MoCA), our model demonstrated predictive capability (F1 = 0.56), suggesting potential for speech-based cognitive monitoring. This comprehensive evaluation establishes both the capabilities and current limitations of speech-based Parkinson's disease assessment, providing a reproducible framework for future clinical development.

Indexed as

LinguisticsParkinson DiseaseSpeechAutoencoderFemaleHumansLanguageMaleCross-linguisticMasked autoencodersParkinson’s diseaseSelf-supervised learningSpeech

Identifiers

PMID41372338
PMCPMC12780117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.